Heart Disease
Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent
Published in Medical Letter on the CDC and FDA, September 13th, 2009
Abbott (NYSE:ABT) announced that it has received approval from Health Canada for the XIENCE V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD). XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials. Abbott will launch XIENCE V in Canada immediately.
"XIENCE V is an important next-generation treatment option combining impressive deliverability with demonstrated efficacy and safety," said Guy Leclerc, M.D., FRCPC, FACC, interventional cardiologist and associate...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- US Army Medical Research Institute of Infectious Diseases
Single host gene may hold key to treating both ebola and anthrax infections - Alcoholism
Research reports from Duke University provide new insights into alcoholism - Bioengineering
ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis - Chronic Obstructive Pulmonary Disease
Four Studies Published in the Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations - Depression
New depression research from University of Leicester discussed - Diabetes
Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
